Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

'EMT Paramedic Training' In California Information is Now Available for Prospective Students to See.

(EMAILWIRE.COM, April 11, 2012 ) Clarkston, Washington -- According to the United States Department of Labor, Employment of Emergency Medical Technicians (EMTs) and EMT paramedics is expected to grow by 19 percent between 2006 and 2016, which is faster than the average for all occupations. Regardless of the current economic challenges for jobs and employment, pursing EMT and EMT paramedic certification is a worthy career path.

California has one of the largest EMT/EMS services in the entire country and the state is continually hiring certified EMT personnel. EMT training and EMT paramedic training, licensing, and certification in the state of California are governed by the Emergency Medical Services Authority or EMSA. This state bureau has the responsibility of managing the entire EMS system for the state of California.

Both EMTs and EMT paramedics must complete a CA EMT training program that is state accredited in order to be certified. California EMT training alone is not sufficient; it requires a state accredited program or courses. The state of California and the EMSA also require the individual who has completed EMT training to pass the National Registry of Emergency Medical Technicians (NREMT) exam and recognizes the exam certification if taken in other states.
California EMT training applicants who wish to take the EMT certification test are first required to have 110 hours of EMT training instructional study, and another 10 hours of medical training studies. Paramedic training in California requires a minimum of 1,090 hours for training.

It is becoming increasingly difficult for emergency medical services to recruit and retain unpaid volunteers because of the amount of EMT training and EMT paramedic training, and the large time commitment these positions require. Not to mention liability. As a result, more paid EMTs and paramedics are needed. Furthermore, as a large segment of the population—aging members of the baby boom generation—becomes more likely to have medical emergencies, demand will increase for EMTs and paramedics. There will still be demand for part-time, volunteer EMTs and paramedics in rural areas and smaller metropolitan areas.

Job prospects for EMTs and paramedics should be very favorable and job opportunities should be best in private ambulance services. Competition will be greater for jobs in local government, including fire, police, and independent third-service rescue squad departments, which tend to have better salaries and benefits. EMTs and paramedics who have advanced EMT training education and paramedic training, such as Paramedic level certification, should enjoy the most favorable job prospects, as employees and patients demand higher levels of care before arriving at the hospital.

About EMT Paramedic Training:

Our website, EMT Paramedic Training, offers current updates for EMT training, paramedic training, and EMT paramedic schools and programs. Recent posts include details on California paramedic colleges, as well as EMT training programs from around the United States and internationally.

JR Consumer Resources Inc.
Linda Phillips Dahl
(208) - 746 - 7971
paramedicschools@cableone.netlvassit@cableone.net

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.


Senegal monitors contacts of 1st Ebola patient
1 Sep 2014 at 10:27am

DAKAR, Senegal (AP) ? Senegalese authorities on Monday were monitoring everyone who was in contact with a student infected with Ebola who crossed into the country, and who has lost three family members to the disease.



Human Trial for Ebola Vaccine to Begin This Week
1 Sep 2014 at 10:13am

GlaxoSmithKline Makes Vaccine Stockpiles



Parents of seriously ill British boy resist extradition from Spain
1 Sep 2014 at 10:06am

The British parents who sparked a major manhunt by taking their seriously ill son out of hospital last week have asked a Spanish court not to extradite them to the United Kingdom, a judicial source said on Monday. Brett and Naghemeh King are wanted in the United Kingdom after removing their son Ashya, 5, who is suffering from a brain tumour, from Southampton General Hospital in southern England on Thursday, raising fears his life could be at risk. "They have said they don't want to be handed over to the British authorities," the source told Reuters. A panel of three judges will now have to decide whether to extradite the parents to the United Kingdom from Madrid, a process which could take weeks, said the source.



Pricing is key for new heart drugs challenging cheap generics
1 Sep 2014 at 9:57am

While new treatments on show in Barcelona are certainly moving cardiovascular medicine forward after a series of setbacks in recent years, cardiologists say that cost will be key in determining how widely they are used. ?We are entering a new era of treatment and, of course, it will cost a lot of money, which is a problem,? said Michel Bertrand, emeritus professor at the University of Lille and a past president of the European Society of Cardiology (ESC). Hopes have spiked for a heart failure drug from Novartis and an innovative class of injectable anti-cholesterol agents known as PCSK9 inhibitors after the release of data at the ESC's annual meeting indicated that they can save more lives than standard therapies. Novartis's new heart failure drug LCZ696, for example, was tested in a pivotal trial against enalapril, a generic drug in the so-called ACE inhibitor class, a month's supply of which can be bought at Wal-Mart stores for only $4.



Poor response to Ebola causing needless deaths: World Bank head
1 Sep 2014 at 9:47am

By Daniel Flynn and Tim Cocks DAKAR/LAGOS (Reuters) - The world's "disastrously inadequate response" to West Africa's Ebola outbreak means many people are dying who could easily be saved, the head of the World Bank said on Monday, as Nigeria confirmed another case of the highly contagious virus. In a newspaper editorial, World Bank President Jim Yong Kim said Western healthcare facilities would easily be able to contain the disease, and he urged wealthy nations to share knowledge and resources to help African countries tackle it. ...



Parents of ill UK boy fight extradition from Spain
1 Sep 2014 at 8:32am

LONDON (AP) ? The parents of a child suffering from a severe brain tumor signaled Monday they would defy efforts to force them to return to Britain, days after their family fled to seek a novel kind of radiation treatment for the 5-year-old boy.



Drama of mother starving baby grips Venice fest
1 Sep 2014 at 8:13am

By Michael Roddy VENICE (Reuters) - A film portraying New York City mother who starves her baby because she thinks he is saint-like and food contains impurities has caused a stir at the Venice Film Festival for its switch from light romance to painful psychosis. "Hungry Hearts", by Italian director Saverio Costanzo, is one of two Italian films shown so far this week that are among 20 films competing for the top Golden Lion award at the world's oldest film festival. It stars Adam Driver, who will be in the next "Star Wars" series, and Italian actress Alba Rohrwacher as his wife. The film, which was shot for a budget of under 1 million euros ($1.3 million), starts off in rom-com style when Driver's character Jude, who works as an engineer, and Rohrwacher's Mina, who works at the Italian embassy, are both accidentally locked in the toilet of a Chinese restaurant.



Ebola health workers should get danger money, expert says
1 Sep 2014 at 8:08am

By Misha Hussain DAKAR (Thomson Reuters Foundation) - Doctors and nurses fighting the world's biggest outbreak of the Ebola virus in West Africa should get incentives including better pay, insurance and access to the new Ebola drug ZMapp, an international health expert said. The hemorrhagic fever, spread through the blood, sweat and vomit of the sick, has killed more than 1,550 people since March, including more than 120 health workers. Johan von Schreeb, who has traveled to the region to advise officials on how to manage the deadly epidemic, said if health workers were not protected and remunerated for their dangerous work, they could not be expected to report for duty. "Modern mobile phone technology can be used to track who is coming to work as well as transferring money directly so they can be paid on a performance-based system on top of their normal salaries," he told Thomson Reuters Foundation from Sierra Leone, where he is providing technical support for the outbreak.


Exercise to reap the heart-health benefits of wine, study says
1 Sep 2014 at 8:08am

At the European Society of Cardiology Congress, researchers from the Czech Republic presented a first of its kind study in which they concluded that wine has its greatest cardiovascular benefits for those who exercise. "This is the first randomised trial comparing the effects of red and white wine on markers of atherosclerosis in people at mild to moderate risk of CVD," says Professor Milos Taborsky, Director of the Internal Cardiology Clinic of the University Hospital and Palacky University in Olomouc. "We found that moderate wine drinking was only protective in people who exercised. Red and white wine produced the same results."



Pistachios may help reduce diabetes risk: study
1 Sep 2014 at 7:29am

By Kathryn Doyle NEW YORK (Reuters Health) - For people who may be headed for type 2 diabetes, regularly eating pistachios might help turn the tide, according to a new trial from Spain. People with so-called prediabetes have blood sugar levels higher than normal but not yet in the diabetes range. If they do nothing, 15 to 30 percent will develop diabetes within five years, according to the U.S. In the new Spanish study, people with prediabetes who ate about two ounces of pistachios daily showed significant drops in blood sugar and insulin levels and improvements in insulin and glucose processing.


Nigeria records another Ebola case in oil city, 16 cases in total
1 Sep 2014 at 6:45am
Nigeria has a third confirmed case of Ebola disease in the oil hub of Port Harcourt, bringing the country's total confirmed infections to 16, with around 200 people under surveillance, the health minister said on Monday. A doctor in Port Harcourt died last week after treating a contact of the Liberian-American man who was the first recorded case of the virus in Africa's most populous country. Patrick Sawyer, the first case, came in from Liberia, then collapsed at Lagos airport on July 20. The shift to Port Harcourt shows how easily containment efforts can be undermined.

India's Cipla launches copy of GSK's top asthma drug in Germany, Sweden
1 Sep 2014 at 6:14am
India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc's Advair, a move that will further dent sales of the British firm's top-selling product. Cipla's drug will be marketed under the name Serrofloin in Germany and Salmeterol/Fluticasone Cipla in Sweden, the Mumbai-based company said in a statement on Monday. In December, Denmark became the first European country to approve for sale a generic version of GlaxoSmithKline's $8 billion-a-year Advair, and analysts have been expecting more such approvals.


Novartis Japan admits concealing drug side effects
1 Sep 2014 at 6:13am

The Japanese unit of Swiss pharma giant Novartis has admitted it did not report more than 2,500 cases of serious side effects in patients using its leukaemia and other cancer drugs, reportedly including some fatalities. The revelations, which marked the latest in a string of scandals at the company's Japanese subsidiary, come after local authorities slapped the firm on the wrist, saying it had to clean up its operations. On Friday, Novartis issued a statement saying it had failed to report to regulators at least 2,579 cases where patients had suffered serious potential side effects from its drugs. Japan's Jiji Press news agency said they included some fatal cases, without specifying a figure.



Tests show no sign of Ebola in Swedish man
1 Sep 2014 at 2:46am

Medical authorities in the Swedish capital said on Monday tests on a man brought into hospital over the weekend and suspected of potentially carrying Ebola showed no signs the deadly disease. The Swedish man, whose name was not disclosed, had recently traveled to a "risk area" for the virus and had been taken to the Karolinska University Hospital in Stockholm suffering from a fever, sparking suspicions of Ebola. Stockholm county council said in a statement the man would continue to be treated at the hospital to ascertain the cause of his symptoms. More than 1,500 people have died in an Ebola outbreak in West Africa since March.



'Most exciting ever' Novartis drug points to huge sales
1 Sep 2014 at 2:21am

By Ben Hirschler BARCELONA (Reuters) - Sales forecasts for Novartis's new heart failure drug are being ramped up by analysts after strikingly good clinical trial results for a medicine doctors expect to transform treatment of the deadly disease. David Epstein, Novartis' head of pharmaceuticals, said the launch of the drug next year promised to be the company's most exciting ever and profit margins on the medicine would be good. The results of a keenly-awaited clinical trial on LCZ696 were released at the annual meeting of the European Society of Cardiology on Saturday and published in the New England Journal of Medicine with a glowing editorial. Investigators working on the study and the company itself believe it has potential to replace drugs that have been central to treating heart failure for a quarter of century, opening up a multi-billion dollar sales opportunity.


Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright © 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC